Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
ANAHEIM, Calif., Aug. 24, 2011 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) announced today that executive management will
present at the following investor conferences in early September:
The Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York
City. Don M. Bailey, President and Chief Executive Officer, is scheduled to
provide an overview of the Company on Wednesday, September 14, 2011 at 8:00 a.m.
ET. Presentations at this conference are not available by webcast.
UBS Global Life Sciences Conference at the Grand Hyatt in New York City. Mr.
Bailey is scheduled to present on Monday, September 19, 2011 at 10:30 a.m. ET. A
live webcast and subsequent archived replay of the presentation will be
accessible at questcor.com, in the "Investor Relations" section under
"Events & Presentations."
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary
product helps patients with serious, difficult-to-treat medical conditions.
Questcor's primary product is H.P. Acthar? Gel (repository corticotropin
injection), an injectable drug that is approved by the FDA for the treatment of
19 indications. Of these 19 indications, Questcor currently generates
substantially all of its net sales from three indications: the treatment of acute
exacerbations of multiple sclerosis in adults, the treatment of nephrotic
syndrome, and the treatment of infantile spasms in children under two years of
age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a
diuresis or a remission of proteinuria in the nephrotic syndrome without uremia
of the idiopathic type or that due to lupus erythematosus." Questcor is also
exploring the use of Acthar to treat systemic lupus erythematosus, for which
Acthar is approved as both a maintenance therapy and to treat exacerbations.
Questcor is also exploring the possibility of developing markets for other
on-label indications and the possibility of pursuing FDA approval of additional
indications not currently on the Acthar label where there is high unmet medical
need. For more information, please visit questcor.com.
SOURCE Questcor Pharmaceuticals, Inc. |
